Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,833.00+1.20%ETH$2,463.31+2.38%GOLD$4,411.10+0.54%OIL$99.32-3.04%
Smart Investors Daily
GN

NASDAQ · GNPX

Genprex, Inc.

Healthcare · Biotechnology

$3.41

Up+$0.10 (+3.02%)

Updated Sep 17, 2026, 11:46 AM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.29M
P/E ratio
-0.15
Dividend yield
0.00%
52-week range
$0.42 – $12.61
Volume
27.4K
Avg. volume
716.01K

Price performance

GNPX price history

1M range · 0 trading sessions · Daily adjusted prices

GNPX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest GNPX news

The latest Smart Investors Daily articles mentioning GNPX.

Stock researchCompany · Overview

GNPX research

Overview

Company profile and research snapshot.

Company profile

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.65
Implied upside
—
Analysts
7
GNPX recent ratings
DateFirmRatingTarget
May 17, 2024HC Wainwright & Co.Buy—
May 15, 2024HC Wainwright & Co.Buy—
Apr 4, 2024HC Wainwright & Co.Buy—
Apr 3, 2024HC Wainwright & Co.Buy—
Mar 25, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), today announced that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16 in New York City. Genprex is a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes. The Company's lead oncology program is in clinical developmen

Yahoo · Aug 3, 2026

Genprex Shares Rise After Collaboration With Roche Diagnostics

Genprex Inc. (NASDAQ:GNPX) shares gained 3% on Monday after the clinical-stage biotechnology company announced a collaboration with Roche Diagnostics to validate biomarkers designed to improve patient selection in clinical trials for non-small cell lung cancer (NSCLC).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By